Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Семаглутид и сердечно-сосудистые исходы у пациентов с сахарным диабетом 2 типа
2016-09-16
SCID: 54.1/8s5qcesr
Discuss with AI
major adverse cardiovascular eventsnoninferiority cardiovascular outcomesoral semaglutiderandomized double-blind placebo-controlled trialtype 2 diabetes
Figures from the paper
Abstract (AI)
BACKGROUND: Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide. METHODS: We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven, randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular risk (age of ≥50 years with established cardiovascular or chronic kidney disease, or age of ≥60 years with cardiovascular risk factors only). The primary outcome in a time-to-event analysis was the first occurrence of a major adverse cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The trial was designed to rule out 80% excess cardiovascular risk as compared with placebo (noninferiority margin of 1.8 for the upper boundary of the 95% confidence interval for the hazard ratio for the primary outcome). RESULTS: A total of 3183 patients were randomly assigned to receive oral semaglutide or placebo. The mean age of the patients was 66 years; 2695 patients (84.7%) were 50 years of age or older and had cardiovascular or chronic kidney disease. The median time in the trial was 15.9 months. Major adverse cardiovascular events occurred in 61 of 1591 patients (3.8%) in the oral semaglutide group and 76 of 1592 (4.8%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.57 to 1.11; P<0.001 for noninferiority). Results for components of the primary outcome were as follows: death from cardiovascular causes, 15 of 1591 patients (0.9%) in the oral semaglutide group and 30 of 1592 (1.9%) in the placebo group (hazard ratio, 0.49; 95% CI, 0.27 to 0.92); nonfatal myocardial infarction, 37 of 1591 patients (2.3%) and 31 of 1592 (1.9%), respectively (hazard ratio, 1.18; 95% CI, 0.73 to 1.90); and nonfatal stroke, 12 of 1591 patients (0.8%) and 16 of 1592 (1.0%), respectively (hazard ratio, 0.74; 95% CI, 0.35 to 1.57). Death from any cause occurred in 23 of 1591 patients (1.4%) in the oral semaglutide group and 45 of 1592 (2.8%) in the placebo group (hazard ratio, 0.51; 95% CI, 0.31 to 0.84). Gastrointestinal adverse events leading to discontinuation of oral semaglutide or placebo were more common with oral semaglutide. CONCLUSIONS: In this trial involving patients with type 2 diabetes, the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo. (Funded by Novo Nordisk; PIONEER 6 ClinicalTrials.gov number, NCT02692716.).
Key Findings
1
All-cause mortality was lower with oral semaglutide than with placebo (23/1591 [1.4%] vs 45/1592 [2.8%]; HR 0.51, 95% CI 0.31–0.84).
2
Gastrointestinal adverse events leading to discontinuation were more common with oral semaglutide than with placebo.
3
In patients with type 2 diabetes at high cardiovascular risk, oral semaglutide did not have a higher cardiovascular risk than placebo (noninferiority achieved; HR for primary outcome 0.79, 95% CI 0.57–1.11; P<0.001 for noninferiority).
4
Oral semaglutide was associated with fewer cardiovascular deaths than placebo (15/1591 [0.9%] vs 30/1592 [1.9%]; HR 0.49, 95% CI 0.27–0.92).
5
There was no significant reduction in nonfatal myocardial infarction with oral semaglutide (37/1591 [2.3%] vs 31/1592 [1.9%]; HR 1.18, 95% CI 0.73–1.90).
6
There was no significant reduction in nonfatal stroke with oral semaglutide (12/1591 [0.8%] vs 16/1592 [1.0%]; HR 0.74, 95% CI 0.35–1.57).
Research Object
Once-daily oral semaglutide administered to patients with type 2 diabetes at high cardiovascular risk
Research Subject
Cardiovascular outcomes and safety, specifically incidence of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, and related adverse events compared with placebo
Publication Details
Publication Date
2016-09-16
Journal
Publisher
ISSN
Cited by
6867
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Cited by16
2018 ESC/ESH Guidelines for the management of arterial hypertension2018
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2020
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD2019
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2018
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association2021
Obesity Phenotypes, Diabetes, and Cardiovascular Diseases2020
Glucagon-like peptide 1 (GLP-1)2019
The Discovery and Development of Liraglutide and Semaglutide2019
The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update2021
Safety of Semaglutide2021
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes2025
Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement2025
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health2025
The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications2026
GLP-1 Receptor Agonists: Clinical Considerations and Risk Management for Patients Undergoing Ophthalmic Surgery2026
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease2023